e-7010 and Hematologic-Diseases

e-7010 has been researched along with Hematologic-Diseases* in 1 studies

Trials

1 trial(s) available for e-7010 and Hematologic-Diseases

ArticleYear
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).
    Pediatric blood & cancer, 2014, Volume: 61, Issue:6

    ABT-751, an orally bioavailable sulfonamide binds the colchicine site of beta-tubulin and inhibits microtubule polymerization. Prior phase I studies established the recommended dose in children with solid tumors as 200 mg/m(2) PO daily × 7 days every 21 days and subjects with neuroblastoma experienced prolonged stable disease. We conducted a phase 2 study (NCT00436852) in children and adolescents with progressive neuroblastoma to determine if ABT-751 prolonged the time to progression (TTP) compared to a hypothesized standard based on a historical control population.. Children and adolescents (n = 91) with a median (range) age 7.7 (2.3-21.5) years and progressive neuroblastoma were enrolled and stratified by disease status into disease measureable by CT/MRI (n = 47) or disease assessable by (123) I-metaiodobenzylguanine scintigraphy (MIBG, n = 44). Response was evaluated using RECIST for measureable disease and the Curie score for MIBG-avid disease.. ABT-751 was well tolerated. The objective response rate was 7%. The median TTP was 42 days (95% CI: 36, 56) in the measureable disease stratum and 45 days (95% CI: 42, 85) in the MIBG-avid disease stratum. TTP was similar to the historical control group (n = 136, median TTP 42 days). For the combined strata (n = 91), 1-year progression free survival (PFS) was 13 ± 4% and overall survival (OS) was 48 ± 5%.. The low objective response rate and failure to prolong TTP indicate that ABT-751 is not sufficiently active to warrant further development for neuroblastoma. However, this trial demonstrates the utility of TTP as the primary endpoint in phase 2 trials in children and adolescents with neuroblastoma.

    Topics: Adolescent; Antineoplastic Agents; Biomarkers; Capsules; Child; Child, Preschool; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Nervous System Diseases; Neuroblastoma; Quality of Life; Recurrence; Salvage Therapy; Sulfonamides; Suspensions; Treatment Failure; Tubulin Modulators

2014